In the past decade, there has been a growing interest in the application of continuous processing in the pharmaceutical industry with 100s millions ..
of investments and several products delivered to the market using this technology. Sanofi R&D is building capacities to perform future GMP clinical batches using this technology. The first investment was completed last year, and we are in the process of expansion. It is a really changing time for science at Sanofi. We are not only thinking machine; to enhance our ability to always produce best quality drugs to our patient, we are also implementing digital twin system, tracking and controlling the quality of our product at any moment of time. He started his career at Pfizer in 2003 as part of the process development team working on the development of the flow team. Since Flavien, worked for Novartis, GSK and more recently Sanofi.